Skip to main content

Advertisement

SpringerLink
Log in

Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Ezrin is a cytoskeleton linker protein that is actively involved in the metastatic process of cancer cells. We have searched for a prognostic value of ezrin and some of its partners: α-smooth muscle actin and CD44H in 37 patients with an osteosarcoma. Automate immunohistochemistry (IHC) with anti-ezrin, α-smooth muscle actin and CD44H antibodies was performed in 66 specimens: 37 biopsies before chemotherapy, 16 resected tumours of “poor” responders and 13 metastases. The messenger RNA (mRNA) levels of ezrin of 13 frozen biopsies and 4 metastases were evaluated by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR). All results were correlated to the following clinical data. Ezrin expression by IHC was found in 62% of 37 biopsies in the different histological subtypes. A good correlation was found between positive or negative samples by IHC and mRNA levels. Ezrin expression was recorded in 84.5% of metastastic samples. The mean expression of ezrin was higher in metastases than biopsies (p = 0.024). In multivariate analysis, ezrin was an independent prognostic marker for event-free survival and overall survival (OS) with p < 0.001 and p = 0.003, respectively, and α-smooth muscle actin for OS only (p = 0.024). Our findings suggest that ezrin and α-smooth muscle actin are predictive IHC prognostic markers for patients with an osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Antonescu CR, Erlandson RA, Huvos AG (1997) Primary leiomyosarcoma of bone: a clinicopathologic, immunohistochemical, and ultrastructural study of 33 patients and a literature review. Am J Surg Pathol 21:1281–1294

    Article  PubMed  CAS  Google Scholar 

  2. Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C, Manfrini M (1997) Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 79:245–254

    Article  PubMed  CAS  Google Scholar 

  3. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K (1996) Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848–858

    PubMed  CAS  Google Scholar 

  4. Bouvier-Labit C, Liprandi A, Monti G, Pellissier JF, Figarella-Branger D (2002) CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans. J Neurooncol 60:127–134

    Article  PubMed  Google Scholar 

  5. Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, Maale GE, Spanier S, Neff JR (1997) Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 95:74–87

    Article  PubMed  CAS  Google Scholar 

  6. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159

    Article  PubMed  CAS  Google Scholar 

  7. Eikmans M, Baelde HJ, Hagen EC, Paul LC, Eilers PH, De Heer E, Bruijn JA (2003) Renal mRNA levels as prognostic tools in kidney diseases. J Am Soc Nephrol 14:899–907

    Article  PubMed  CAS  Google Scholar 

  8. Greenland S, Mickey RM (1989) Re: “The impact of confounder selection criteria on effect estimation. Am J Epidemiol 130:1066

    PubMed  CAS  Google Scholar 

  9. Harris MB, Gieser P, Goorin AM, Ayala A, Shochat SJ, Ferguson WS, Holbrook T, Link MP (1998) Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 16:3641–3648

    PubMed  CAS  Google Scholar 

  10. Hasegawa T, Hirose T, Seki K, Hizawa K, Ishii S, Wakabayashi J (1997) Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas. Cancer Detect Prev 21:280–287

    PubMed  CAS  Google Scholar 

  11. Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10:201–204

    Article  PubMed  CAS  Google Scholar 

  12. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O (2005) Ezrin in primary cutaneous melanoma. Mod Pathol 18:503–510

    Article  PubMed  CAS  Google Scholar 

  13. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750–3759

    PubMed  CAS  Google Scholar 

  14. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182–186

    Article  PubMed  CAS  Google Scholar 

  15. Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH (2002) Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res 396:184–190

    Article  PubMed  Google Scholar 

  16. Kim MS, Song WS, Cho WH, Lee SY, Jeon DG (2007) Ezrin Expression Predicts Survival in Stage IIB Osteosarcomas. Clin Orthop Relat Res 459:229–236

    Article  PubMed  Google Scholar 

  17. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M, El-Rifai W (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235–240

    Article  PubMed  CAS  Google Scholar 

  18. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H (1999) Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 125:646–652

    Article  PubMed  CAS  Google Scholar 

  19. Le Deley M, Guinebretiere J, Gentet J, Pacquement H, Pichon F, Marec-Berard P, Entz-Werle N, Schmitt C, Brugieres L, Vanel D, Dupouy N, Tabone M et al (2007) SFOP OS94: a randomised trial comparing preoperative high-dose Methotrexate plus Doxorubicine to high-dose Methotrexate plus Etoposide and Ifosfamide in osteosarcoma patients. European J Cancer 43:752–761

    Article  CAS  Google Scholar 

  20. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606

    Article  PubMed  CAS  Google Scholar 

  21. Mangeat P, Roy C, Martin M (1999) ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9:187–192

    Article  PubMed  CAS  Google Scholar 

  22. Martin TA, Harrison G, Mansel RE, Jiang WG (2003) The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46:165–186

    Article  PubMed  Google Scholar 

  23. Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin North Am 44:973–989

    Article  PubMed  CAS  Google Scholar 

  24. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5–15

    PubMed  CAS  Google Scholar 

  25. Nathrath MH, Kuosaite V, Rosemann M, Kremer M, Poremba C, Wakana S, Yanagi M, Nathrath WB, Hofler H, Imai K, Atkinson MJ (2002) Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man. Oncogene 21:5975–5980

    Article  PubMed  CAS  Google Scholar 

  26. Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L, Ekman P (2004) Expression of ezrin in prostatic intraepithelial neoplasia. Urology 63:609–612

    Article  PubMed  Google Scholar 

  27. Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW, Park YK (2006) Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract 202:509–515

    Article  PubMed  CAS  Google Scholar 

  28. Peng TS, Qiu JS, Wu HX, Liang HZ, Luo CQ (2002) [Expressions of CD44s, MMP-9, and Ki-67: possible association with invasion, metastasis, and recurrence of osteosarcoma]. Ai Zheng 21:745–750

    PubMed  Google Scholar 

  29. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84

    PubMed  CAS  Google Scholar 

  30. Rocchi P, Muracciole X, Fina F, Mulholland DJ, Karsenty G, Palmari J, Ouafik L, Bladou F, Martin PM (2004) Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene 23:9111–9119

    Article  PubMed  CAS  Google Scholar 

  31. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230

    Article  PubMed  CAS  Google Scholar 

  32. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2177

    Article  PubMed  CAS  Google Scholar 

  33. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP (1991) Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9:1766–1775

    PubMed  CAS  Google Scholar 

  34. Shiratori H, Koshino T, Uesugi M, Nitto H, Saito T (2001) Acceleration of lung metastasis by up-regulation of CD44 expression in osteosarcoma-derived cell transplanted mice. Cancer Lett 170:177–182

    Article  PubMed  CAS  Google Scholar 

  35. Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Bohling T, Karaharju E, Hyytinen E, Knuutila S et al (1995) Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 55:1334–1338

    PubMed  CAS  Google Scholar 

  36. Taylor WF, Ivins JC, Unni KK, Beabout JW, Golenzer HJ, Black LE (1989) Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst 81:21–30

    Article  PubMed  CAS  Google Scholar 

  37. Vaheri A, Carpen O, Heiska L, Helander TS, Jaaskelainen J, Majander-Nordenswan P, Sainio M, Timonen T, Turunen O (1997) The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 9:659–666

    Article  PubMed  CAS  Google Scholar 

  38. Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65:2406–2411

    Article  PubMed  CAS  Google Scholar 

  39. Watanabe K, Tajino T, Sekiguchi M, Suzuki T (2000) h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors. Am J Clin Pathol 113:663–668

    PubMed  CAS  Google Scholar 

  40. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW (2002) Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62:2281–2286

    PubMed  CAS  Google Scholar 

  41. Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C (2005) Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11:6198–6204

    Article  PubMed  CAS  Google Scholar 

  42. Yamamura H, Yoshikawa H, Tatsuta M, Akedo H, Takahashi K (1998) Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer 79:245–250

    Article  PubMed  CAS  Google Scholar 

  43. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10:175–181

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful to P. Morando and Marie Thérèse Brel for technical assistance.

Author information

Authors and Affiliations

  1. Service d’Oncologie Médicale Adulte CHU Timone, APHM, Marseilles, France

    Sébastien Salas & Florence Duffaud

  2. Laboratoire de Biopathologie de l’Adhésion et de la Signalisation, EA3281, IPHM, Faculté de Médecine Timone, 27, Bd Jean Moulin, 13005 , Marseilles, France

    Catherine Bartoli, Arlette Calisti, Dominique Figarella-Branger & Corinne Bouvier

  3. Service d’Anatomie Pathologique et de Neuropathologie,CHU Timone, Marseilles, France

    Jean-Laurent Deville, Dominique Figarella-Branger & Corinne Bouvier

  4. Service de Santé Publique et d’Information Médicale, Unité de Biostatistique, CHU Timone, Marseilles, France

    Jean Gaudart

  5. Laboratoire de transfert en Oncologie Biologique, IFR Jean Roche, Marseilles, France

    Fréderic Fina

  6. Service de Chirurgie Orthopédique pédiatrique, CHU Timone, Marseilles, France

    Gérard Bollini

  7. Service de Chirurgie Orthopédique adulte, Hôpital la Conception, Marseilles, France

    Georges Curvale

  8. Service d’Oncologie pédiatrique, CHU Timone, APHM, Marseilles, France

    Jean-Claude Gentet

Authors
  1. Sébastien Salas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Bartoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Laurent Deville
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Gaudart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fréderic Fina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arlette Calisti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gérard Bollini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Georges Curvale
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Claude Gentet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Florence Duffaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dominique Figarella-Branger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Corinne Bouvier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Corinne Bouvier.

Additional information

This work was supported by Institutional grants of EA3281, by the “Appel d’offre APHM 2005” and by the Philippe Daher’s foundation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salas, S., Bartoli, C., Deville, JL. et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch 451, 999–1007 (2007). https://doi.org/10.1007/s00428-007-0474-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-007-0474-8

Keywords

Search

Navigation